
Edwards Lifesciences (EW) Stock Forecast & Price Target
Edwards Lifesciences (EW) Analyst Ratings
Bulls say
Edwards Lifesciences is experiencing positive momentum in its financial performance, with operating margins expanding by 100 basis points, supported by foreign exchange benefits, and aligning with the company's strategic growth targets. The firm anticipates approximately 10% average annual sales growth, excluding foreign exchange impacts, driven by an increasing contribution from its structural heart therapies and a recovery in TAVR procedure volumes due to enhanced hospital capacities and favorable clinical data. Additionally, the growth of the Cordella heart failure monitoring device, alongside reaffirmed 2025 sales guidance, indicates a promising outlook for sustained revenue growth and EPS leverage as the company continues to strengthen its market position.
Bears say
The financial outlook for Edwards Lifesciences appears negative due to several key factors that may hinder growth. Firstly, there are concerns regarding the TAVR business growth outlook, which may be lower than investor expectations, as well as a potentially smaller total addressable market than currently projected. Additionally, the company's innovation pipeline for tricuspid and mitral valve repair products may experience delays, and the challenging global regulatory and reimbursement environment could further impede the adoption of new technologies.
This aggregate rating is based on analysts' research of Edwards Lifesciences and is not a guaranteed prediction by Public.com or investment advice.
Edwards Lifesciences (EW) Analyst Forecast & Price Prediction
Start investing in Edwards Lifesciences (EW)
Order type
Buy in
Order amount
Est. shares
0 shares